In this issue
- Preparing your practice for the new era of theranostics
- Darolutamide approved for non-metastatic Castration-resistant prostate cancer
{optin-asset[id:44,label:Download PDF,linkClass:button download]}
{optin-asset[id:44,label:Download PDF,linkClass:button download]}